Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Nov;9(7):475-87.
doi: 10.2174/138920208786241243.

Genetics and molecular biology of tuberous sclerosis complex

Affiliations

Genetics and molecular biology of tuberous sclerosis complex

Valerio Napolioni et al. Curr Genomics. 2008 Nov.

Abstract

Tuberous Sclerosis Complex is a multisystem disorder exhibiting a wide range of manifestations characterized by tumour-like lesions called hamartomas in the brain, skin, eyes, heart, lungs and kidneys. Tuberous Sclerosis Complex is genetically determined with an autosomal dominant inheritance and is caused by inactivating mutations in either the TSC1 or TSC2 genes. TSC1/2 genes play a fundamental role in the regulation of phosphoinositide 3-kinase (PI3K) signalling pathway, inhibiting the mammalian target of rapamycin (mTOR) through activation of the GTPase activity of Rheb. Mutations in TSC1/2 genes impair the inhibitory function of the hamartin/tuberin complex, leading to phosphorylation of the downstream effectors of mTOR, p70 S6 kinase (S6K), ribosomal protein S6 and the elongation factor binding protein 4E-BP1, resulting in uncontrolled cell growth and tumourigenesis.Despite recent promising genetic, diagnostic, and therapeutic advances in Tuberous Sclerosis Complex, continuing research in all aspects of this complex disease will be pivotal to decrease its associated morbidity and mortality. In this review we will discuss and analyse all the important findings in the molecular pathogenesis of Tuberous Sclerosis Complex, focusing on genetics and the molecular mechanisms that define this multisystemic disorder.

Keywords: Tuberous sclerosis; genetics; germ-line mosaicism; hamartin; multifactorial disease; mutations; rapamycin.; tuberin.

PubMed Disclaimer

Figures

Fig. (1).  Biochemical structure of hamartin and tuberin.
Fig. (1). Biochemical structure of hamartin and tuberin.
In this figure are rappresented the regulatory phosphorylation sites and respective kinases responsible for their phosphorylation.
Fig. (2)
Fig. (2)
Mutation spectra of TSC1 and TSC2.
Fig. (3).  Tuberous sclerosis complex signalling.
Fig. (3). Tuberous sclerosis complex signalling.
Figure showing signalling pathways involved in the regulation of TSC complex controlling mammalian target of rapamycin (mTOR) activity. PI3K=phosphatidylinositol 3-kinase. PIP2=phosphatidyl-inositol (4,5) biphosphate. PIP3= phosphatidyl-inositol (3,4,5) triphosphate. PDK1= phosphoinositide-dependent protein kinase 1. PTEN= Phosphatase and tensin homolog. AKT=Protein kinase B. REDD-1=DNA-damage inducible transcript 4 protein. RSK-1=ribosomal protein S6 kinase alpha-1. LKB1=Serine/threonine-protein kinase 11. ERK=extracellular signal-related kinase. Rheb=Ras homologue enriched in brain. S6K1=ribosomal protein S6 kinase beta-1. 4E-BP1=eukaryotic translation initiation factor 4E-binding protein 1. eEF-2K=elongation factor 2 kinase. CDK1= Cyclin dependent Kinase 1.

References

    1. Curatolo P. London: Mac Keith Press; 2003. Tuberous Sclerosis Complex: From Basic Science to Clinical Phenotypes.
    1. Narayanan V. Tuberous sclerosis complex: Genetics to pathogenesis. Pediatr. Neurol. 2003;29:404–9. - PubMed
    1. Gomez MR, Sampson JR, Whittemore VH. Tuberous Sclerosis Complex. Oxford: Oxford University Press; 1999.
    1. Curatolo P, Verdecchia M, Bombardieri R. Tuberous sclerosis complex: a review of neurological aspects. Eur. J. Pediatr. Neurol. 2002;6:15–23. - PubMed
    1. Joinson C, O’Callaghan FJ, Osborne JP, Martyn C, Harris T, Bolton PF. Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex. Psychol. Med. 2003;33:335–44. - PubMed